Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy

Clinical Cancer Research

Volumn 19, Issue 4, 2013, Pages 938-948

  Mahfouz, Reda Z ^a   Jankowska, Ania ^a   Ebrahem, Quteba ^a   Gu, Xiaorong ^c   Visconte, Valeria ^a   Tabarroki, Ali ^a   Terse, Pramod ^c   Covey, Joseph ^d   Chan, Kenneth ^e   Ling, Yonghua ^e   Engelke, Kory J ^f   Sekeres, Mikkael A ^a   Tiu, Ramon ^a   MacIejewski, Jaroslaw ^a   Radivoyevitch, Tomas ^b   Saunthararajah, Yogen ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f Smithers Viscient   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; AZACITIDINE; CYTARABINE; CYTIDINE DEAMINASE; DNA METHYLTRANSFERASE 1; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CYCLE S PHASE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; EPIGENETICS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MATHEMATICAL MODEL; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY;

ANIMALS; AZACITIDINE; CYTARABINE; CYTIDINE; CYTIDINE DEAMINASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84874029247     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1722     Document Type: Article

References (49)

1. Santi DV, Garrett CE, Barr PJ. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 1983; 33:9-10.
2. Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, et al. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood 2012;119:1240-7.
3. Covey JM, D'Incalci M, Tilchen EJ, Zaharko DS, Kohn KW. Differences in DNA damage produced by incorporation of 5-aza-20-deoxycytidine or 5, 6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res 1986;46:5511-7.
4. Schermelleh L, Haemmer A, Spada F, Rosing N, Meilinger D, Rothbauer U, et al. Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation. Nucleic Acids Res 2007;35:4301-12.
5. Momparler RL, Goodman J. In vitro cytotoxic and biochemical effects of 5-aza-20-deoxycytidine. Cancer Res 1977;37:1636-9.
6. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
7. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, et al. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS ONE 2009;4: e4563.
8. Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. Targeting of 5-aza-20-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 2010;38:4313-24.
9. Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, et al. p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia 2011;25:1739-50.
10. Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia 2012;26:244-54.
11. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106: 1794-803.
12. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia- Manero G, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27:3842-8.
13. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7.
14. Camiener GW, Smith CG. Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmacol 1965;14:1405-16.
15. Neil GL, Moxley TE, Kuentzel SL, Manak RC, Hanka LJ. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice. Cancer Chemother Rep 1975; 59:459-65.
16. Rogstad DK, Herring JL, Theruvathu JA, Burdzy A, Perry CC, Neidigh JW, et al. Chemical decomposition of 5-aza-20-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol 2009;22:1194-204.
17. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-20-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 2006;20:1117-26.
18. Neil GL, Moxley TE, Manak RC. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice. Cancer Res 1970;30:2166-72.
19. Wong PP, Currie VE, Mackey RW, Krakoff IH, Tan CT, Burchenal JH, et al. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. Cancer Treat Rep 1979;63:1245-9.
20. Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998;26:421-5.
21. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006;12:1794-803.
22. Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, et al. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol 2009;144:388-94.
23. Mercier C, Raynal C, Dahan L, Ortiz A, Evrard A, Dupuis C, et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007;17:841-4.
24. Metharom E, Galettis P, Manners S, Jelinek M, Liauw W, de Souza PL, et al. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patientswith variant alleles of cytidine deaminase c.79A>C. Asia Pac J Clin Oncol 2011;7:65-74.
25. Zhang L, Sinha V, Forgue ST, Callies S, Ni L, Peck R, et al. Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 2006;33:369-93.
26. Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, et al. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharmacol 1995;36:425-30.
27. Yoo CB, Chuang JC, Byun HM, Egger G, Yang AS, Dubeau L, et al. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) 2008;1:233-40.
28. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
29. Richards DA, Sherwood RA, Ndebele D, Rocks BF. Determination of plasma cytidine deaminase activity by HPLC. Biomed Chromatogr 1987;2:148-51.
30. Ciccolini J, Dahan L, Andre N, Evrard A, Duluc M, Blesius A, et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 2010;28:160-5.
31. Steuart CD, Burke PJ. Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol 1971;233:109-10.
32. Ohta T, Hori H, Ogawa M, Miyahara M, Kawasaki H, Taniguchi N, et al. Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. Oncol Rep 2004;12:1115-20.
33. Yin B, Tsai ML, Hasz DE, Rathe SK, Le Beau MM, Largaespada DA. A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia. Leukemia 2007;21:1093-7.
34. Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 2004;64:728-35.
35. + haemopoietic stem cells in their metabolism of cytosine arabinoside. Br J Haematol 1999;105:388-93.
36. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-20-deoxycytidine in human cancer cell lines. Blood 2009;113: 659-67.
37. Kreis W, Lesser M, Budman DR, Arlin Z, DeAngelis L, Baskind P, et al. Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response. Cancer Chemother Pharmacol 1992;30:126-30.
38. Klein HU, Ruckert C, Kohlmann A, Bullinger L, Thiede C, Haferlach T, et al. Quantitative comparison of microarray experiments with published leukemia related gene expression signatures. BMC Bioinformatics 2009;10:422.
39. Raza A, Maheshwari Y, Preisler HD. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood 1987;69:1647-53.
40. Head DR, Jacobberger JW, Mosse C, Jagasia M, Dupont W, Goodman S, et al. Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis. Bone Marrow Res 2011;2011:950934.
41. Dimopoulou I, Efstathiou E, Samakovli A, Dafni U, Moulopoulos LA, Papadimitriou C, et al. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 2004;15:1250-5.
42. Pitako JA, Haas PS, Van den BJ, Muller-Berndorff H, Kundgen A, Germing U, et al. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine. Ann Hematol 2005;84 Suppl 1:25-31.
43. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-20-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005;84 Suppl 1:9-17.
44. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22:538-43.
45. Nosslinger T, Tuchler H, Germing U, Sperr WR, Krieger O, Haase D, et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 2010;21:120-5.
46. Schmetzer O, Florcken A. Sex differences in the drug therapy for oncologic diseases. Handb Exp Pharmacol 2012;214:411-42.
47. Ebrahem Q, Mahfouz RZ, Ng KP, Saunthararajah Y. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget 2012;3: 1137-45.
48. Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, et al. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)-a pilot study. Leukemia 1991;5:991-8.
49. Lemaire M, Momparler LF, Raynal NJ, Bernstein ML, Momparler RL. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 2009;63:411-6.